ABBVAbbVieFinished
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 79 (final count)
- Started
- Oct 19, 2021
- Main results expected
- Dec 12, 2024
- Fully finished
- Dec 12, 2024
- Results posted
- Jan 9, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1])
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05041257 · record last updated 2026-01-09 · checked 2026-11-09 15:47 UTC